BMB Reports Papers in Press available online.

Search Papers In Press
This galley proof is being listed electronically before publishing the final manuscript (It's not final version).

Cancer Immunotherapy with T-cell targeting cytokines: IL-2 and IL-7
Ji-Hae Kim 1 (Graduate student), Kun-Joo Lee 2 (Graduate student), Seung-Woo Lee 1,2,* (Professor)
1Department of Life Sciences and 2Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology (POSTECH), Pohang 37673, Korea
Clinical trials have demonstrated that an increased number of effector cells, especially tumor-specific T cells, is positively linked with patients' prognosis. Although the discovery of checkpoint inhibitors (CPIs) has led to encouraging progress in cancer immunotherapy, the lack of T cells, the target for CPIs, is a limitation for patients with poor prognosis. Since interleukin (IL)-2 and IL-7 are cytokines that target many aspects of T-cell responses, they have been used to treat cancers. In this review, we focus on the basic biology of how these cytokines regulate T-cell response and on the clinical trials using the cytokines against cancers. Further, we introduce several recent studies that aim to improve cytokines' biological activities and find the strategy for combination with other therapeutics.
Abstract, Accepted Manuscript [Submitted on November 18, 2020, Accepted on December 28, 2020]
  Copyright © KSBMB. All rights reserved. / Powered by INFOrang Co., Ltd